Crystal structure determination of mebendazole form a using high-resolution synchrotron X-ray powder diffraction data

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1734-1744

  Ferreira, Fabio Furlan ^a   Antonio, Selma Gutierrez ^b   Rosa, Paulo César Pires ^c   De Paiva Santos, Carlos Oliveira ^b  

^a LABORATÓRIO NACIONAL DE LUZ SÍNCROTRON   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Ab initio calculations; Anthelmintic drug; Crystal structure; Crystallography; Mebendazole; Polymorph A; Polymorphism; Quantitative phase analysis; Synchrotron; X ray powder diffractometry

Indexed keywords

MEBENDAZOLE;

ARTICLE; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DRUG FORMULATION; DRUG STRUCTURE; HYDROGEN BOND; SYNCHROTRON; X RAY POWDER DIFFRACTION;

EID: 77949807907     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21902     Document Type: Article

References (44)

1. Al-Badr AA, Tariq M. 1987. Analytical profiles of mebendazole. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic Press. pp. 291-325.
2. Rodriguez-Caabeiro F, Criado-Fornelio A, Jimenez-Gonzalez A, Guzmán L, Igual A, Pérez A, Pujol M. 1987. Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms. Chemotherapy 33:266-271.
3. Himmelreich M, Rawson BJ, Watson TR. 1977. Polymorphic forms of mebendazole. Aust J Pharm Sci 6:123-125.
4. Evans AC, Finscham JE, Dhamsay MA, Liebenberg W. 1999. Anthelmintic efficacy of mebendazole depends on molecular polymorph. S Afr Med J 89: 1118-1118.
5. Brusau EV, Camí GE, Narda GE, Cuffini S, Ayala AP, Ellena J. 2008. Synthesis and characterization of a new mebendazole salt: Mebendazole hydrochloride. J Pharm Sci 97:542-552.
6. Costa J, Fresno M, Guzmán L, Igual A, Oliva J, Vidal P, Pérez A, Pujol M. 1991. Polymorphic forms of mebendazole: Analytical aspects and toxicity. Cir Far 49:415-424.
7. Charoenlarp P, Waikagul J, Muennoo C, Srinophakun S, Kitayaporn D. 1993. Efficacy of single-dose mebendazole, polymorphic forms A and C, in the treatment of hookworm and Trichuris infections. J Trop Med Pub Health 24:712-716.
8. Swanepoel E, Liebenberg W, de Villiers MM. 2003. Quality evaluation of generic drugs by dissolution test: Changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur J Pharm Biopharm 55:345-349.
9. 3. Cryst Struct Comm 9:181-186.
10. Caira MR, Dekker TG, Liebenberg W. 1998. Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid. J Chem Crystallogr 28:11-15.
11. Martins FT, Neves PP, Ellena J, Camí GE, Brusau EV, Narda GE. 2009. Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C. J Pharm Sci 98:2336-2344.
12. Aboul-Enein HY, Bunaciu AA, Fleschin S. 2002. Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods. Biopolymers 67:56-60.
13. FDA. 2007. Guidance for Industry: ANDAs: Pharmaceutical Solid Polymorphism - Chemistry, Manufacturing, and Controls Information. ed., Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
14. David WIF, Shankland K, van de Streek J, Pidcock E, Motherwell WDS, Cole JC. 2006. DASH: A program for crystal structure determination from powder diffraction data. J Appl Crystallogr 39: 910-915.
15. Aarts E, Korst J. 1988. Simulated annealing and Boltzmann machines: A stochastic approach to combinatorial optimization and neural computing. Chichester, UK: John Wiley & Sons.
16. Van Laarhoven PJ, Aarts EH. 1987. Simulated annealing: Theory and applications. Dordrecht, Holland: Kluwer Academic Publishers.
17. Rietveld HM. 1969. A profile refinement method for nuclear and magnetic structures. J Appl Crystallogr 2:65-71.
18. 6 double perovskite. J Synchrotron Radiat 13:46-53.
19. Giles C, Yokaichiya F, Kycia SW, Sampaio LC, Ardiles-Saravia DC, Franco MKK, Neuenschwander RT. 2003. High-resolution X-ray diffraction beamline at the LNLS for the study of charge, orbital and magnetic structures. J Synchrotron Radiat 10:430-434.
20. Rodrigues R. 2004. Polimorfismo do Mebendazol. Formil Química Ltda. Private Communication. Jandira, SP, Brazil.
21. Boultif A, Louër D. 1991. Indexing of powder diffraction patterns for low-symmetry lattices by the successive dichotomy method. J Appl Crystallogr 24:987-993.
22. Toby BH. 2005. CMPR - A powder diffraction toolkit. J Appl Crystallogr 38:1040-1041.
23. Shirley R, Louër D. 1978. New powder indexing programs for any symmetry which combine grid-search with successive dichotomy. Acta Crystallogr A 34:S382.
24. Shirley R. 2002. The Crysfire 2002 system for automatic powder indexing: User's manual. Version 4.06. GuildFord Surrey, England: The Lattice Press.
25. de Wolff PM. 1968. A simplified criterion for the reliability of a powder pattern indexing. J Appl Crystallogr 1:108-113.
26. Kohlbeck F, Hörl EM. 1978. Trial and error indexing program for powder patterns of monoclinic substances. J Appl Crystallogr 11:60-61.
27. Hahn T. 1983. International tables for crystallography. 1st edition. Dordrecht, Holland: The International Union of Crystallography. p. 871.
28. Pawley GS. 1981. Unit-cell refinement from powder diffraction scans. J Appl Crystallogr 14:357-361.
29. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. 2006. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668-D672.
30. Spek AL. 2003. Single-crystal structure validation with the program PLATON. J Appl Crystallogr 36: 7-13.
31. Krivý I, Gruber B. 1976. A unified algorithm for determining the reduced (Niggli) cell. Acta Crystallogr A 32:297-298.
32. Larson AC, Von Dreele RB. 2001. General Structure Analysis System (GSAS) (ReportLAUR86-748). Los Alamos, NM: Los Alamos National Laboratory.
33. Toby BH. 2001. EXPGUI, a graphical user interface for GSAS. J Appl Crystallogr 34:210-213.
34. 6 by X-ray powder diffraction. Mater Res Bull 23:447-452.
35. 3. J Appl Crystallogr 20:79-83.
36. Finger LW, Cox DE, Jephcoat AP. 1994. A correction for powder diffraction peak asymmetry due to axial divergence. J Appl Crystallogr 27:892-900.
37. Stephens PW. 1999. Phenomenological model of anisotropic peak broadening in powder diffraction. J Appl Crystallogr 32:281-289.
38. Wright J. 1998. Using the "Plab" (PerL Angles and Bonds) Perl script by Jon Wright for generating bond length and angle restraints macros for GSAS on organic structures. ed.
39. Toby BH. 2006. R factors in Rietveld analysis: How good is good enough? Powder Diffr 21:67-70.
40. Hill RJ, Flack HD. 1987. The use of the Durbin-Watson d statistic in Rietveld analysis. J Appl Crystallogr 20:356-361.
41. Farrugia LJ. 1997. ORTEP-3 for Windows - A version of ORTEP-III with a Graphical User Interface (GUI). J Appl Crystallogr 30:565-565.
42. Bruno IJ, Cole JC, Kessler M, Luo J, Sam Motherwell WD, Purkis LH, Smith BR, Taylor R, Cooper RI, Harris SE, Orpen AG. 2004. Retrieval of crystallographically-derived molecular geometry information. J Chem Inf Comp Sci 44:2133-2144.
43. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
44. Swanepoel E, Liebenberg W, Devarakonda B, de Villiers MM. 2003. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie 58:117-121.